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plasma folate (8.9±3.8 to 34.3±16.5µg/l & 9.9±4.1 to 17.4±7.6µg/l respectively; ∆ high c.f.
low dose p<0.001). Both doses of folic acid significantly (p<0.001) lowered plasma total
homocysteine (12.9±5.6 to 9.9±2.6µmol/l for high dose & 11.7±3.1 to 10.5±1.8µmol/l for
low dose; ∆ high c.f. low dose p=0.219). However, FMD was improved only following high
(99±35 c.f. 24±26µm pretreatment, p<0.001) and not low (42±32 c.f. 26±59µm pretreat-
ment, p=0.264) dose folic acid. No differences between groups were evident for any of
the other parameters measured.
Conclusion: The data demonstrate that high but not low dose folic acid improves endot-
helial function in CAD despite a significant reduction in homocysteine in both treatment
groups. This suggests that the beneficial effects of folic acid on endothelial function occur
via a mechanism that is independent of homocysteine-lowering. These results have
important implications for the current clinical trials of folic acid supplementation using low
dose folic acid.
1159-187 Long-Term Use of Pioglitazone Slows Arteriosclerotic 
Progression in Type 2 Diabetics
Tatsuaki Murakami, Masateru Ohnaka, Fukui Cardiovascular Center, Fukui, Japan
Introduction and hypothesis: Insulin resistance is thought to be highly involved in arte-
riosclerotic processes, but the long-term effects of insulin sensitizing agents remain
unknown. We assessed hypothesis that long-term use of pioglitazone, an insulin sensi-
tizer, slows ultrasonic manifestation of atherosclerosis.
Methods: Thirty type-2 diabetic patients with suspected coronary artery disease were
randomized to group-P where they received pioglitazone (30mg per day) for more than 1
year, or to group-C where they continued therapy without thiazolidinedione for more than
1 year. We noninvasively ultrasonic quantified flow mediated dilation of brachial artery
after 5 minutes forearm occlusion (FMD) and we also quantified arterial stiffness by bra-
chial-to-ankle pulse wave velocity (PWV). Changes in FMD and PWV from the baseline
through the follow-up point were compared between the 2 groups. Results: Group-P
(n=15) manifested good compliance to the treatment and improvements in insulin resis-
tant variables represented by HOMA-IR while group-C showed no improvement. FMD
was improved after medication in group-P (p<0.01) but not in group-C (p=ns). PWV
decreased in group-P (p=0.02) but increased in group-C (p=0.03). 
Conclusion: In conclusion long-term pioglitazone use improves endothelial function and
arterial wall compliance, which may have beneficial potentials for management of arterio-
sclerosis in type-2 diabetics.
1159-188 Grape Seed and Skin Extracts Alter Platelet Function 
and Release of Reactive Oxygen Species
Olga Vitseva, Sonia Varghese, Subrata Chakrabati, John Folts, Jane E. Freedman, 
Boston University School of Medicine, Boston, MA
Background: Moderate red wine consumption is inversely associated with coronary
ischemia. Red wine and purple grape juice (PGJ) contain polymeric flavonoids with anti-
oxidant properties believed to be protective against cardiovascular events. Acute cardiac
events are also associated with decreased platelet-derived nitric oxide (NO) release. In
this study, the effects of extracts from grape skins or seeds on platelet function, NO, and
superoxide release were determined.
Methods and Results: Incubation of platelets with seed (100 mg/L) or skin (250 mg/L)
extract led a decrease in platelet aggregation of 65% ± 7% and 49% ± 9%, respectively
(n=6; P<0.001). Grape seed or skin extract increased platelet-derived NO release by
126% ± 19% and 92% ± 20%, respectively (n=5, P<0.001). Platelet incubation with
extracts led to a marked decrease in superoxide release from 73 ± 6 to 2 ± 3 for grape
seeds and to 7.3 ± 6.4 for grape skin (arb. Chemilum. units; n=5, P<0.0001). These
effects were dose-dependent for both grape extracts. Coincubation with seeds and skins
led to additive effect on inhibition of platelet aggregation, enhanced NO release, and
ablated superoxide production, but did not significantly alter release of aggregation
induced soluble CD40 ligand, a marker of inflammatory-thrombotic interactions.
Conclusion: The skins and seeds from grapes inhibit platelet function and increase bio-
active NO. These effects may be due to the markedly decreased release of superoxide
anion or via another antioxidant-sparing mechanism. Red wine has been shown to
enhance vascular function via a NO-dependent mechanism and the extracts derived from
grapes appear to provide similar beneficial properties.
1159-189 Echocardiographic Correlates of Pulmonary 
Hypertension in 2,337 Patients
James N. Mohn, Richard W. Asinger, Charles A. Herzog, Bradley A. Bart, Hennepin 
County Medical Center, Minneapolis, MN
Background: Echocardiographic findings in a large population of unselected patients
with pulmonary hypertension (PH) have not been reported, and are herein described.
Methods: Using our echocardiographic database, we retrospectively identified all adult
patients having measurable tricuspid regurgitation (n=14,869). Patients with estimated
RV-RA gradients _ 40 mmHg were defined as having PH (n=2,337); those having gradi-
ents _ 20 were defined as having no PH (n=3,136). Demographic information, clinical
data and codified echocardiographic findings were analyzed for their association with PH.
Differences between cohorts were assessed using the t-test and chi square test for con-
tinuous and dichotomous variables, respectively.
Results: The PH cohort was significantly older (64.3±16.9 yrs vs. 47.1 ± 17.7 yrs) and
had a small but significant male preponderance (50.3% vs. 45.2%). Body mass index
(BMI) was significantly greater in the PH group (30.2 ± 10.2 vs. 27.3± 7.3), and grouped
analyses of echocardiographic parameters are presented below.
Conclusion: PH was present in over 15% of patients with measurable tricuspid regurgi-
tation. Compared to patients without PH, there are striking differences in age, sex, weight
and measures of atrial, LV, RV and valvular morphology and function. A significant num-
ber of PH patients (25.3%) lacked left-sided pathology that could contribute to the pres-
ence of PH. To our knowledge, this study represents the largest cohort of unselected PH
patients described. 
1159-190 Role of the 807 C/T Polymorphism of Glycoprotein Ia/IIa 
on Platelet Function Following Clopidogrel Loading 
Dose in Patients Undergoing Coronary Stenting
Dominick J. Angiolillo, Antonio Fernández-Ortiz, Esther Bernardo, Celia Ramirez, 
Elisabetta Trabetti, Chiara Stranieri, Manel Sabate, Fernando Alfonso, Pierfranco 
Pignatti, Carlos Macaya, San Carlos University Hospital, Madrid, Spain, Univeristy of 
Verona, Verona, Italy
Background: The 807 C/T polymorphism of the glycoprotein (GP) Ia/IIa is the major
platelet-collagen receptor. In particular, T allele carriers have increased receptor density
and thrombotic risk. Aim of the study was to assess the role of the 807 C/T polymorphism
on platelet aggregation (PA) following a 300 mg clopidogrel loading dose (LD) after coro-
nary stenting (CS). Methods: The 807 C/T genotype was assessed in 44 patients (P). P
were divided into 2 groups: carriers (CT + TT genotypes) and non-carriers (CC genotype)
of the T allele. All P were on aspirin and those receiving GP IIb/IIIa blockers were not
included. PA (expressed as %) was assessed at baseline (B), and 4hrs and 24hrs follow-
ing LD by light transmittance aggregometry using ADP (6 µM) and collagen (6 µg/mL) as
agonists. Results: There were 32/44 T allele carriers and 12/44 CC homozygotes. ADP-
induced PA did not differ between groups (Table). Following collagen stimuli, PA was
higher (*p<0.05) in T allele carries following LD (Table). PA reduced (#p<0.001) at 4 and
24 hrs in all P except after collagen stimuli in T allele carriers. There were no differences
in fibrinogen and von Willebrand factor levels, platelet count, and clinical status. Conclu-
sions: The T allele of the GP Ia/IIa gene is associated with increased platelet reactivity
and a lower response to clopidogrel LD following collagen stimuli. This suggests that T
allele carriers have a more extensive platelet adherence to fibrillar collagens which may
contribute to their increased thrombotic risk.
1159-191 Effect of a Single High-Fat Meal on Endothelial 
Microparticles as a Marker of Endothelial Injury
Arley A. Peter, Alexandre Ferreira, Salim Virani, Eduardo de Marchena, Santiago Garcia, 
Reyan Ghany, Josh Purow, Joaquim Jimenez, Yeon Ahn, Jackson Memorial Hospital 
University of Miami, Miami, FL
BACKGROUND: This study was designed to evaluate a possible relationship between
levels of CD31+/CD42b- Endothelial Microparticles (EMP), markers of endothelial injury,
and cholesterol levels in healthy volunteers.
METHODS: A total of 23 healthy subjects without any major risk factors or previous car-
diovascular risk factors were evaluated. A fasting cholesterol profile and EMP levels were
measured in all subjects. Endothelial microparticles were measured by flow cytometry
using fluorescent monoclonal antibodies.
RESULTS: Subjects were divided in two different groups according to fasting total cho-
lesterol. Group A had cholesterol levels below 200 mg/dl (157 + 31) and group B had
serum cholesterol equal or greater than 200 mg/dl ( 258.4 + 11.14); p: < 0.0001. The
measured levels of EMP (x10^6/mL) were 0.388824 + 0.053954 in group A and 0.964 +
0.185148589 in group B (P< 0.0001). The 17 subjects in group A were then fed a high fat
meal containing 900calories, 50g of fat, 14g of saturated fat, and 255mg of cholesterol.
The measured levels of EMP (x10^6/mL) fasting, at one hour and three hours were
0.388824 + 0.053954, 0.541176 +0.138649 and 0.676667 +0.158505, respectively.
Baseline
group-P
Follow-up
group-P
Baseline
group-C
Follow-up
group-C
FMD 4.1±1.6% 7.1±2.7% 1727±269cm/s 1664±234cm/s
PWV 4.1±1.8% 4.2±1.7% 1710±232cm/s 1797±215cm/s
Clinical and Echocardiographic 
Findings
Pulmonary 
Hypertension
(n=2,337)
No Pulmonary 
Hypertension
(n=3,136)
p-value
Age in years (mean ± SD) 64.3 ± 16.9 47.1 ± 17.7 <.001
Gender Female (%) 49.7% 54.8% <.001
BMI (Kg/m2 , mean ± SD) 30.2 ± 10.2 27.3 ± 7.3 <.001
Abnormal LV Morphology or Function 69.4% 30.6% <.001
Abnormal RV Morphology or Function 35.9% 11.3% <.001
Abnormal Atrial Morphology or Rhythm 58.0% 23.3% <.001
Moderate or Severe Left Sided Valvular 
Disease
35.0% 7.8% <.001
Pericardial Abnormalities 20.5% 9.5% <.001
Any L-Sided Abnormalities (Valvular, 
Structural or Functional)
74.7% 41.0% <.001
ADP B 4 hrs 24 hrs
CC 61±16 43±13# 32±9#
CT+TT 55±18 42±18# 35±19#
Collagen B 4 hrs 24 hrs
CC 42±15 30±13# 31±14#
CT+TT 47±19 43±21* 46±26*
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There was a statistically significant difference when comparing EMP levels fasting, at one
hour (p= 0.0002) and three hours (p< 0.0001) after the high fat meal. When low fat meal
was given, there was not statistical difference when comparing EMP levels fasting and
one hour and three hours after low meal.
CONCLUSION: EMP are shed in the circulation and may represent an early marker of
endothelial injury. There is a direct correlation between cholesterol and EMP levels in
healthy volunteers. A single high fat meal may lead to a detectable elevation of EMP in
the circulation even in subjects with normal fasting baseline total cholesterol.
1159-192 The Influence of Simvastatin on the Angiotensin AT1 
Receptor Density, Oxidative Stress, and Endothelial 
Function in Patients With Coronary Disease
Marek Kiliszek, Michal Maczewski, Grzegorz Styczynski, Monika Duda, Andrzej 
Beresewicz, Grzegorz Opolski, Medical University of Warsaw, Warsaw, Poland, Medical 
Centre of Postgraduate Education, Warsaw, Poland
Background: On the base of experimental studies we formulated the hypothesis on the
development of the endothelial dysfunction: LDL cholesterol -> angiotensin AT1 receptors
(AT1R) -> oxidative stress -> endothelial dysfunction. We tested this hypothesis in
patients (pts) with stable angina. We tested also whether statin: (i) improves endothelial
function by reducing oxidative stress and (ii) that this effect is due to the reduction in
angiotensin AT1R density.
Methods: Lipid profile, platelet AT1 receptor density, serum F2-isoprostanes (marker of
oxidative stress) and nitrate + nitrite concentration, and brachial artery flow mediated
dilation (FMD, index of endothelial function) were assessed in 20 pts ( LDL cholesterol
75-230 mg%) with proven coronary heart disease, which were not on hypolipemic treat-
ment. These measurements were performed at baseline and after treatment with simvas-
tatin 40mg/24 h for 12 weeks.
Results: At baseline there was a significant linear correlation between (i) LDL cholesterol
concentration and AT1R density (r=0,55; p<0,05) (ii) AT1R density and F2-isoprostanes
concentration (r=0,62; p<0,05) and (iii) F2-isoprostanes and FMD (r= –0,65; p<0,05).
Simvastatin treatment caused a significant reduction in LDL cholesterol (152±39 vs.
89±27mg/dl; p<0,00001), AT1R density (14,42±5,42 vs 7,58±2,68 receptors/platelet;
p<0,00001), F2-isoprostanes (39,85±14,03 vs. 27,90±10,65pg/ml, p=0,017), a significant
improvement in FMD (8,85±4,80% vs 11,04±3,85%; p=0,031), and significant increase in
nitrite + nitrate (17,23±7,53 vs. 20,94±7,93uM; p=0,038). Among these simvastatin-
induced effects, only changes in AT1 receptors and F2-isoprostane concentrations
showed strong linear correlation (r=0,65; p<0,05). Conclusions: For the first time we
have shown in one study that statin causes, in addition to LDL cholesterol reduction and
endothelial function improvement, reduction in AT1R density and oxidative stress. Base-
line results suggest relationship between LDL cholesterol, AT1R density, oxidative stress
and endothelial dysfunction. Our results suggest that simvastatin-induced reduction in
oxidative stress is due to reduction in AT1R density.
1159-193 Simvastatin Combined With Ramipril Improved 
Endothelium-Dependent Vasodilation and Fibrinolysis 
Potential and Reduced Oxidant Stress and Inflammation 
Markers in Hypercholesterolemic Patients
Kwang K. Koh, Seung H. Han, Jeong Y. Ahn, Woong C. Kang, Wook-Jin Chung, Tae H. 
Ahn, Eak K. Shin, Gachon Medical School, Incheon, South Korea
Background: Because the mechanisms of the biological effects of statin and antiotensin
converting enzyme inhibitor therapies differ, we studied the vascular responses to these
therapies in hypercholesterolemic patients.
Methods: We administered simvastatin 20 mg and placebo or ramipril 10 mg daily during
2 months with washout 2 months to 50 hypercholesterolemic patients. This study was
randomized, double-blind, placebo-controlled, crossover in design.
*=P<0.05;**=P<0.01;***=P<0.001 vs. Baseline. Data= mean±SEM.
Results: Simvastatin alone did not reduce blood pressure, however, simvastatin com-
bined with ramipril significantly reduced blood pressure after 2 months administration
compared with baseline. Compared with each baseline, simvastatin alone or combined
with ramipril significantly changed lipoproteins, and improved the percent flow-mediated
dilator response to hyperemia by 30±5% and by 53±6%, respectively (both P<0.001) and
reduced plasma levels of malondialdehyde (MDA) levels by 4±7% (P=0.026) and by
25±4% (P<0.001), respectively and MCP-1 levels by 3±3% and by 12±2%, respectively
(P=0.049 and P=0.001, respectively), and C-reactive protein levels by -4±14% and by
26±5%, respectively (P=0.036 and P<0.001, respectively), and PAI-1 antigen levels by -
7±7% and by 17±5%, respectively (P=0.828 and P<0.001, respectively). However, simv-
astatin combined with ramipril significantly changed more the percent flow-mediated dila-
tor response to hyperemia and plasma levels of MDA, MCP-1, CRP, and PAI-1 antigen
than simvastatin alone independent of lowering blood pressure.
Conclusions; Compared with simvastatin alone, simvastatin combined with ramipril sig-
nificantly improved endothelium-dependent vasodilation and fibrinolysis potential and
reduced plasma levels of oxidant stress and inflammation markers in hypercholester-
olemic patients.
Baseline1 Statin+Placebo Baseline2 Statin+Ramipril
Apo B (mg/dl) 131±4 89±3*** 129±4 92±3***
FMD (%) 4.81±0.24 6.02±0.29*** 4.56±0.22 6.58±0.25***
Nitrate (umol/l) 92±7 83±6 89±6 74±5*
MDA (υM) 1.36±0.08 1.17±0.07* 1.45±0.09 1.01±0.07***
MCP-1 (pg/ml) 194±8 178±5* 202±8 174±6***
PAI-1 (pg/ml) 64±4 63±4 68±4 53±3***
1159-194 Cystatin C, a Novel Risk Marker for Mortality in the 
General Population: Data Obtained From the PREVEND 
Study
Hans L. Hillege, Jacobien C. Verhave, Stephan J.L. Bakker, Ron T. Gansevoort, Dirk J. 
van Veldhuisen, Paul E. de Jong, Dick de Zeeuw, University Hospital Groningen, 
Groningen, The Netherlands
Serum cystatin C (CysC) can generally be recommended as a marker of renal function.
We recently showed that CysC was independently of renal function positively associated
with a number of cardiovascular risk factors like age, male sex, weight, smoking and C-
reactive protein (CRP) levels. We questioned therefore whether CysC, CRP and serum
creatinine (SCr), another serum marker of renal function, carry similar prognostic signifi-
cance for mortality. Data were obtained from the PREVEND study, a longitudinal popula-
tion based cohort study in the city of Groningen, the Netherlands (n=8,592, age 28-75
yr). Preliminary results of a random sample of 6,135 subjects are presented. Median fol-
low-up time was 5.2 yrs. A total of 180 subjects died. CRP, CysC and SCr were evaluated
by dividing the whole range of measurements into 5 for sex stratified groups covering the
0 to 50th, 50 to 75th, 75 to 87.5th, 87.5 to 95th and 95 to 100th percentile. After adjustment
for age and sex, CysC , CRP but not SCr contributed independently to an increased risk
of death (P< 0.001, P< 0.0001 vs P=0.688, respectively). CysC and CRP remained both
statistically significant in the multivariate adjusted model. The figure below gives the age
and sex adjusted estimated HR (95% CI) of both CysC and CRP on the risk of death
using 0 to 50th percentile as the reference group. In conclusion, CysC is a novel, inde-
pendent and sensitive prognostic marker, a property that can not be explained by inflam-
mation or renal function. Further mechanistic studies are needed.
1159-195 Spironolactone Improves Coronary Endothelial 
Function in Patients With Chronic Heart Failure
Keishi Saihara, Shuichi Hamasaki, Takashi Yoshitama, Sanemasa Ishida, Akiko 
Yoshikawa, Tetsuro Kataoka, Koji Orihara, Naoya Oketani, Tsuyoshi Fukudome, 
Masakazu Ogawa, Hideki Okui, Takuro Shinsato, Shinichi Minagoe, Chuwa Tei, 
Kagoshima University, Kagoshima City, Japan
Background: Spironolactone was reported to improve prognosis in patients with chronic
heart failure.However, the effect of spironolactone on coronary artery function has not be
fully elucidated. Therefore we examined the effect of spironolactone on coronary flow
with Doppler flow wire. Method: Thirty-nine patients treated with chronic heart failure
(NYHA class I-II) without significant coronary artery stenosis (% diameter stenosis<30%)
underwent Doppler flow study of the left anterior descending coronary artery. Thirteen
patients with taking spironolactone served as spironolactone group, and 26 patients with-
out taking spironolactone served as control group. Vascular reactivity was examined by
intra-coronary administrating papaverine (12.5 mg / 20 sec), acetylcholine (Ach) (3 and
30 mg / 2 min), and nitroglycerine (200 mg / 20 sec) using a Doppler guidewire. Coronary
blood flow (CBF) at control, percent increase in CBF and in coronary artery diameter
(CAD) were calculated. The comparisons between groups were analyzed with the Mann-
Whitney U test. Results: There were no significant differences between the two groups
in age, gender, coronary risk factor, ejection fraction of left ventricle, circulatory drugs,
and CBF at control between two groups. Enddiastolic dimension of left ventricle and left
ventricular mass in spironolactone group were significantly higher than those in control
group (61±6 vs. 51±9 mm. P<0.01, 515±110 vs. 400±156 g, P<0.02, respectively). The
percent increase in CBF and CAD induced by Ach in spironolactone group were signifi-
cantly greater than those in control group (89±119 vs. 5±105%, P<0.05, -8±21 vs. -
41±36%, P<0.03). Whereas, no significant differences were found in reaction induced by
papaverin and nitroglycerin between two groups. Conclusions: These results demon-
strate that spironolactone improves coronary endothelial function in patients with chronic
heart failure.
1159-196 Does Local Hypertriglyceridemia Impair Resistance 
Vessel Endothelial Function in Humans?
Nabil E. Choueiri, Philip Roberts-Thomson, Christine A. Sinkey, William G. Haynes, The 
University of Iowa, Iowa City, IA
Background: Hypertriglyceridemia (HTG) has a modest association with cardiovascular
events. Previous studies showed that systemic HTG induces conduit vessel endothelial
dysfunction within 60 min. However, the effect of HTG on resistance vessels remains
